ABL1 and synucleinopathy: While Nilo treatment leads to dramatic reduction in α-synucleinopathy-related abnormalities in brainstem, analysis of spinal cord reveals that Nilo was not able to reduce the levels of active c-Abl or reduce αS pathology, including accumulation of pS129αS, in spinal cord (Additional file 1: Figures S14 and S15).